ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report

Document Type

Article

Publication Date

3-1-2024

Publication Title

Clinical lung cancer

Abstract

There are few reported cases of ALK gene rearranged (ALK+) non-small cell lung cancer (NSCLC) during pregnancy. There is a lack of information on the safety of ALK inhibitors in pregnant patients. We present a 25-year-old African American woman who was diagnosed with metastatic ALK+ lung adenocarcinoma at 15 weeks of gestation. Treatment with alectinib was initiated at 18 weeks' gestation with resultant radiological treatment response. The patient did not experience any adverse effects from alectinib during her pregnancy. An elective induction of labor at 39 weeks resulted in an uncomplicated vaginal delivery. This case adds to available data and provides insight on the safety of using alectinib in a pregnant, ALK+ NSCLC patient, allowing the patient to continue her pregnancy to term while treating advanced lung adenocarcinoma.

Medical Subject Headings

Female; Humans; Pregnancy; Adult; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Anaplastic Lymphoma Kinase; Receptor Protein-Tyrosine Kinases; Adenocarcinoma of Lung; Carbazoles; Protein Kinase Inhibitors; Piperidines

PubMed ID

38057186

ePublication

ePub ahead of print

Volume

25

Issue

2

First Page

77

Last Page

77

Find It @ Sladen

Share

COinS